| Autor: |
Sharma, Sonali, Pavlasova, Gabriela Mladonicka, Seda, Vaclav, Cerna, Katerina Amruz, Vojackova, Eva, Filip, Daniel, Ondrisova, Laura, Sandova, Veronika, Kostalova, Lenka, Zeni, Pedro F., Borsky, Marek, Oppelt, Jan, Liskova, Kvetoslava, Kren, Leos, Janikova, Andrea, Pospisilova, Sarka, Fernandes, Stacey M., Shehata, Medhat, Rassenti, Laura Z., Jaeger, Ulrich, Doubek, Michael, Davids, Matthew S., Brown, Jennifer R., Mayer, Jiri, Kipps, Thomas J., Mraz, Marek |
| Zdroj: |
Blood; May 2021, Vol. 137 Issue: 18 p2481-2494, 14p |
| Abstrakt: |
B-cell receptor (BCR) signaling and T-cell interactions play a pivotal role in chronic lymphocytic leukemia (CLL) pathogenesis and disease aggressiveness. CLL cells can use microRNAs (miRNAs) and their targets to modulate microenvironmental interactions in the lymph node niches. To identify miRNA expression changes in the CLL microenvironment, we performed complex profiling of short noncoding RNAs in this context by comparing CXCR4/CD5 intraclonal cell subpopulations (CXCR4dimCD5brightvs CXCR4brightCD5dimcells). This identified dozens of differentially expressed miRNAs, including several that have previously been shown to modulate BCR signaling (miR-155, miR-150, and miR-22) but also other candidates for a role in microenvironmental interactions. Notably, all 3 miR-29family members (miR-29a, miR-29b, miR-29c) were consistently down-modulated in the immune niches, and lower miR-29(a/b/c)levels associated with an increased relative responsiveness of CLL cells to BCR ligation and significantly shorter overall survival of CLL patients. We identified tumor necrosis factor receptor–associated factor 4 (TRAF4) as a novel direct target of miR-29sand revealed that higher TRAF4 levels increase CLL responsiveness to CD40 activation and downstream nuclear factor-κB (NF-κB) signaling. In CLL, BCR represses miR-29expression via MYC, allowing for concurrent TRAF4 upregulation and stronger CD40–NF-κB signaling. This regulatory loop is disrupted by BCR inhibitors (bruton tyrosine kinase [BTK] inhibitor ibrutinib or phosphatidylinositol 3-kinase [PI3K] inhibitor idelalisib). In summary, we showed for the first time that a miRNA-dependent mechanism acts to activate CD40 signaling/T-cell interactions in a CLL microenvironment and described a novel miR-29–TRAF4–CD40 signaling axis modulated by BCR activity. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
